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RESPONSE TO RICHARD B. MILLER’S
CHILDREN, ETHICS, AND MODERN
MEDICINE
Paul Lauritzen
Department of Religious Studies
John Carroll University
Although there is much in this volume that would repay careful study, I want in this brief
essay to focus on what I take to be the theoretical heart of the book, namely, Chapter 5, on basic
interests. It is in this chapter that Miller takes up the important task of defending liberalism as a
political theory that can generate an account of pediatric ethics that is compatible with the
religious and moral pluralism of our society. My plan is briefly to set out Miller’s claim that
liberal theory can define both what is permissible and what is impermissible in the medical
treatment of children without endorsing any particular comprehensive theory of the good. I am
deeply sympathetic to his effort to provide a normative account of pediatric ethics along liberal
lines (Miller 2003, 130), but I want to explore the contours of this normative understanding by
focusing on a couple of case studies that may lead us either to question the contrast Miller draws
between basic interests and best interests or to call for a more expansive understanding of basic
interests or both.
In order to understand what Miller is up to in his chapter on basic interests, it is important
to see the dilemma posed for a political liberal wrestling with issues of pediatric ethics. The basic
problem is that in caring for many children and adolescents it will not be possible to rely on a
child’s autonomous choice to secure well-being. Caring for pediatric patients requires promoting
beneficence rather than autonomy, and this in turn requires defining what is in the patient’s
interest, often in the absence of any meaningful measure of how the patient him- or herself
would define this interest. This creates what Miller refers to as “the problem of moral pluralism.”
“Without a socially shared vision of what it means to flourish as a human being,” Miller writes,
“it is impossible to determine how to protect a patient’s interest. What is ‘good’ for a person is
up for grabs in a culture that lacks a shared understanding of the ends of human life, for without
the idea of such ends we cannot determine how to promote that person’s interest” (Miller 2003,
120). In the absence of any shared vision of the good and without any sense of the patient’s own
vision of the good, we seem to be without a moral compass.
I cannot do full justice to Miller’s carefully developed and subtle response to this
problem, but the gist of his solution is that we must distinguish liberalism as a political theory
from liberalism as a comprehensive theory. Liberalism as a political theory is able to maintain
neutrality regarding comprehensive visions of the good while nevertheless identifying primary
goods that we have a duty to provide to those in need. In developing this response, Miller draws
on Rawls’s idea of an “overlapping consensus” of comprehensive theories of the good, a
consensus that supports at least a “thin” theory of the good. Distinguishing between thick and
thin theories of the good allows us to draw a related distinction between basic interests and best
interests. Basic interests are concerned with the primary goods that everyone needs no matter
what his or her comprehensive vision is; best interests necessarily require a more full-bodied
account of the good.

With these distinctions in mind, Miller’s response to the problem of pluralism in pediatric
medicine is this: When we cannot know a child’s or an adolescent’s comprehensive vision of the
good, we have a duty to promote her basic interests, not her best interests. That is, we have a
duty to provide the primary goods that children need and whatever else they may want, now or in
the future. In the case of children, that means “coming to terms with the goods of physical,
intellectual, and emotional welfare; respect; and the right to an open future” (Miller 2003, 126).
I confess that I find this account of political liberalism and its normative commitments
enormously appealing. I especially find it so in a society where some groups appear increasingly
willing to seek to impose their comprehensive visions of the good on others. Nevertheless, I
wonder whether, in the end, Miller’s account of basic interests is substantial enough to secure the
well-being of children in a society that, for all its talk of the importance of children, does not
really value children.
To give a sense of my concern, I want to begin with a case that is only marginally related to
pediatric ethics; it does, however, highlight the difficulty of securing the well-being of children
in our society. The case involves what I sometimes think of as the “silent” sex abuse crisis in the
country. This crisis is not the much-discussed sex abuse scandal in the Catholic Church, but the
almost daily focus on the sexual activities of children on the daytime TV talk shows.¹ Alas, with
ever growing frequency, the daily talk shows exploit children, especially teenage girls, by
encouraging them to recount the salacious details of the sex lives for a studio and TV audience.
Jenny Jones, Maury Povich, Sally Jesse Raphael, Montel Williams, Jerry Springer—all have
aired such shows.
For anyone with even passing acquaintance with these shows, it will come as no surprise
that Jenny, or Jerry will do almost anything to improve ratings. (If you are not familiar with
these shows, the title of a segment from a Jenny Jones show—no doubt run during “sweeps”
week—will give you a sense of this fare: “Somebody Give My Daughter A Whipping, She
Wants to Make Her Money Stripping.”) Now it is perhaps unfair to Miller to suggest that his
account of securing children’s basic interests may require him to shout down Jerry Springer, and
I certainly do not want symbolically to break a chair over Miller’s head, as one of Jerry’s guest
might literally do, but there is a serious issue to be considered here: Can Miller’s account explain
the harm that is done to these teenagers in a way that generates a duty to prevent such
exploitation?
In responding to this question, it is important to note that it would be a mistake to dismiss
such shows as marginal and beneath contempt, for it is not just Jenny and Jerry who exploit
teenagers in this way. Oprah and Dr. Phil do so as well; and whatever you think of these shows,
there is no disputing that they have a huge mainstream following. Yet these two “champions” of
mental health in this country clearly—at least to me it is clear—exploit children. Consider, for
example, a segment on the Oprah show from when Dr. Philwas still a regular on the show.²
Entitled, “Dr. Phil on Alarming Sexual Behavior,” the segment consisted of interviews with three
girls, fourteen and fifteen years old, who appeared on the show with their mothers. The girls
described the way in which they had casually provided boys with oral sex, sometimes in the
school bathroom, sometimes on the bus to or from school. We learn that one of the girls had
begun doing this when she was thirteen years old. The program was punctuated by prerecorded
interviews with other girls and boys who described their various sexual activities and partners.
What should we make of the fact that Dr. Phil interviews teenagers on national television
about their sexual practices? Dr. Phil will, of course, say that he is just “getting real,” that

teenage sexuality is a problem that will not go away by ignoring it. As a parent of teenagers, I
certainly would agree with him about that. Yet, putting teenagers on national television to talk
about their sex lives is arguably to exploit them. It violates their privacy and exposes them to
extraordinary scrutiny at a particularly vulnerable time in their lives. But does it violate their
basic interests? As a political liberal, am I required to ignore the decision of these children’s
parents who, not sharing my vision of the comprehensive good that would lead them to repudiate
such voyeurism, give consent? I do not doubt that Miller would condemn this exploitation of
children, but can he do so given his thin theory of the good and the duty to secure only basic
interests? In short, is tolerating this sort of instrumental use of children and adolescents the price
we pay for the liberal solution to the problem of pluralism? ³
The second set of cases on which I want to focus intersects more directly with Miller’s
work, because the cases involve both medical treatment of, and medical research on, children.
Specifically, I want to pose for Miller’s consideration the use of synthetic growth hormone (GH)
for nonhormone deficient children.⁴ As I understand it, recombinant GH is approved for use in
children for only three conditions: GH deficiency, Turner’s syndrome, and chronic renal disease.
Nevertheless, because biosynthetic GH is now readily available and because there is some
evidence that GH may increase adult height if administered to children who are short but not
suffering from any of the problems for which it is an approved treatment, parents have been
requesting GH treatment for their children and pediatricians have been providing it. Indeed, one
study indicated that 94% of pediatric endocrinologists surveyed would recommend GH therapy
for children with so-called idiopathic short stature (Leschek et al., 3140).
I would be interested in Miller’s reflections on the therapeutic alliance that permits the general
use of GH for children whose only “medical” problem is that they are short. But I want to
sharpen the case by focusing on one clinical trial involving GH that raises serious issues about
whether a duty to promote children’s basic interests is enough. Although I would not go so far as
to call the study a “sanitized form of barbarism,” to borrow Paul Ramsey’s language about
pediatric research, in my view it is a study that should not have been conducted. Because
Miller is such an insightful observer of pediatric medicine and because I think this study poses an
intriguing case for his theory, I am interested to hear what he would say about it.
The study was jointly funded by the National Institute of Child Health and Human
Development and the Eli Lilly and Company Growth Hormone Collaborative Group, and it was
occasioned by the situation I described above. That is, thousands of children of short stature are
receiving GH in this country despite the fact that there is no definitive evidence that GH
increases adult height and despite the fact that there are risks associated with receiving GH.With
that in mind, the authors of this study designed a randomized, double-blind, placebo-controlled
trial to study the effect of GH on adult height in peripubertal children.
Although the results of the study were only recently published (Leschek et al.), the study
itself had been in the works for many years and was controversial from the start (see Prentice et
al. 1989; Tauer 1994; White 1993). The original study design called for recruiting 80 children
ranging in age from 9 to 15 who were not GH deficient but of short stature. The study was to
involve an initial four-day evaluation period at National Institutes of Health (NIH), during which
subjects would undergo routine blood and urine tests, X-rays, MRIs (magnetic resonance
imagings), and behavioral and psychological tests. Each subject was to be photographed nude.
Subjects were to return to NIH at six-month intervals for similar workups. For the study itself,
subjects were to be randomized to either the HG arm or the placebo arm of the study and both
groups would receive subcutaneous injections 3 times per week over the course of study, in some

cases for up to seven years. Although the precise number of injections could not be determined
in advance, the investigators estimated that subjects would receive between 600 and 1,100
injections.
I want shortly to look at how the Institutional Review Board (IRB) and the special review panel
at NIH came to approve this study, but before doing so, let me say that I agree with Miller that
“the first line of moral responsibility falls on investigators and IRBs… not on parents or
guardians who may agree to enroll their children” (Miller 2003, 246). Indeed, I think Miller
shows convincingly that Paul Ramsey got the ethics of pediatric research badly wrong by
focusing on proxy consent instead of on patient benefit. Focusing on the issue of consent,
Ramsey concluded that children may never be subjects of nontherapeutic research because they
are not able to consent to such research and “no parent is morally competent” to consent on their
behalf. However, as Miller points out, the fact that Ramsey allowed parents to consent to
therapeutic research demonstrates that the real issue here is not consent but patient benefit. As
Miller puts it: “Had Ramsey seen matters more clearly, he would have argued that canons of
loyalty to a child in research settings must begin not by focusing on criteria for validating
parental consent, but with determining whether the proposed intervention is in that child’s basic
medical interest” (Miller 2003, 245). I agree with Miller about this.
With this standard in mind, then, we can return to the GH study. We do not know how
the original IRB that approved this study reasoned to its conclusion, but we know that their
conclusion was controversial. In fact, in response to criticism from the Foundation for Economic
Trends and the Physicians Committee for Responsible Medicine, NIH convened a committee to
review the social and ethical issues raised by the GH study. The Review Committee
recommended that the short stature study, as they called it, be allowed to go forward (National
Institutes of Health 1992). Because the Review Committee published its deliberations in a report,
we have an interesting (and unusual) record of moral analysis in this case that deserves attention.
To understand the conclusions reached by the Review Committee, it is necessary to review the
Department of Health and Human Services (DHHS) guidelines for research involving
experimentation on children. (Miller takes these up in chap. 11) According to the relevant
guidelines (45 CFR 46, sec. 46.404–46.406), studies involving experimentation on children may
be undertaken if the research (a) poses only minimal risk (46.404), (b) involves greater than
minimal risk but presents the prospect of direct benefit to the individual subject (46.405), or (c)
involves greater than minimal risk, provides no prospect of direct benefit to the individual
subject, but is likely to yield generalizable knowledge about the subjects’ disorder or condition
(46.406). The Review Committee offered an assessment of the GH study under all three sections,
and their analysis is instructive.
The first issue was whether the short stature study was acceptable because it represented
only minimal risk to the subjects. Here federal guidelines are explicit: “Minimal risk means that
the probability and magnitude of harm or discomfort anticipated in the research are not greater in
and of themselves than those ordinarily encountered in daily life or during the performance of
routine physical or psychological examinations or tests” (46.102). The Review Committee
unanimously concluded that the risks to the subjects were more than minimal. The mere fact that
children enrolled in the study would receive three shots per week, in some cases for up to seven
years, was enough to place the study beyond the threshold of minimal risk. Moreover, the study
could increase self-consciousness about height or reinforce a harmful and misguided view that
the subjects are “abnormal.” As the Review Committee wrote, even though it is “difficult to

weigh or to calculate the probability of these risks,” they are greater than minimal, as defined by
the regulations.
The Review Committee then took up the question of whether the study was acceptable
under 46.405, that is, research involving greater than minimal risk “but presenting the prospect
of direct benefit to the individual subjects.” Once again, federal regulations are explicit, even if
hard to apply.⁵ IRBs may approve research involving greater than minimal risk but promising
direct benefit under three conditions: (a) the risk is justified by the anticipated benefit to the
subjects, (b) the relation of the anticipated benefit to the risk is at least as favorable to subjects as
that presented by available alternative approaches, and (c) adequate provisions are made for
soliciting the assent of the children and permission of their parents or guardians. In applying
46.405, the Review Committee noted two major difficulties. First, the regulations do not spell
out how to determine whether there is a prospect of direct benefit to each individual subject.
Second, balancing benefits against risks in this case is a complex undertaking.
Consider the problem of determining whether there is a likelihood of direct benefit to
each individual in the study. As the Review Committee points out, one obvious question is
whether benefit should be calculated before or after randomization takes place. If the calculation
takes place before randomization, then assuming that GH may be beneficial, each subject in the
protocol has a 50% chance of benefiting. By contrast, if the calculation takes place after
randomization, then the subjects in the placebo arm of the study can expect no benefit, given that
they will not receive the GH.⁶
According to the Committee, the question of whether the short stature study meets the
requirements that either the risk is justified by the anticipated benefit to the subject (46.405(a)) or
that the risk/benefit ratio is at least as good as the available alternative approaches (46.405(b)) is
extremely difficult to answer in light of “the paucity of good data about the probability of risks,
and by the absence of common measures of their significance.” Indeed, a minority of the panel
believed that the risks were justified by the anticipated benefits; another minority believed that
the risks outweighed the benefits; and a third group believed that the calculations were either too
speculative or too evenly divided to reach a definitive conclusion. Nevertheless, the Committee
was able to reach consensus because they interpreted 46.405(a) to be a requirement that the study
be in equipoise.
The claim of equipoise is, of course, central to any defense of randomized clinical trials
(Chard and Lilford 1998; Freedman 1987; Gifford 1995; Karlawish and Lantos 1997). As it is
typically understood, equipoise refers to the fact that there is a genuine null hypothesis being
tested in the study. Because physicians are committed to providing patients with the best possible
treatment, for a randomized clinical trial to be ethically justified there must be uncertainty about
whether a new therapy will be at least as effective as the standard treatment.
When there is no proven treatment, there must be uncertainty that the new therapy will not be
better than no treatment. The Review Committee clearly invoked this traditional understanding
of equipoise. “Clinical equipoise,” they wrote, “exists if, after considering the evidence regarding
the tradeoff and risks for each treatment strategy, there remains sufficient collective uncertainty
regarding which strategy is superior so that opinion would be divided among reasonable medical
experts.” In the case of the short stature study, clinical equipoise would require that there be
genuine medical uncertainty whether providing GH to nonhormonedeficient children is
preferable, given the expected risks and benefits, to not treating at all. And indeed, it was
precisely this uncertainty that led to the initiation of the trial in the first place.

The problem is that by asking primarily about benefit, the framework of equipoise is
likely to obscure the possibility of real harm. So long as there is no proven treatment, evaluating
a traditional placebo-controlled study involves weighing two somewhat uncertain probabilities of
benefit. Asking about equipoise thus involves comparing the study drug to the placebo and
asking whether there is a roughly equal likelihood of benefit from each. So the comparison is
between taking the study drug and taking the placebo. But what about cases, like the short stature
study, where the administration of the placebo itself may cause harm? In such cases, the fact that
the likelihood of benefit is roughly equal between a treatment arm of the study and the placebo
arm cannot be morally determinative.
Where placebos may harm, the choice is not merely between taking the study drug and taking a
placebo. There is a third choice: doing nothing. While not participating in the study is, of course,
always an option with a traditional placebo-controlled trial, not participating and taking a
placebo are essentially the same in the standard drug study, at least with respect to harm. And
this is decidedly not the case in studies where placebos may harm. Although the possibility of
benefit may be roughly equivalent when the two arms are compared, and although participating
in the study may provide greater likelihood of improvement than doing nothing, participating in
such a study will expose a subject to harm that he or she would not be exposed to outside of the
study.
My conclusion is thus that the short stature study should not have been conducted. I am
inclined to think that Miller would agree. For example, at one point, he writes: “The rationale for
allowing nontherapeutic research that includes a minor increase over minimal risk cannot be
justified. According to the federal regulations, studies may impose a ‘minor increase over
minimal risk’ when the research is likely to yield generalizable knowledge about the subject’s
disorder which is of vital importance for understanding or ameliorating that disorder.
This permission allows adults to enroll children if the costs to the research subject are
outweighed by the potential benefits to society and medicine.” But, says Miller, “Justifying
pediatric research in this way instrumentalizes children. It allows the ends to justify the means
and increases risks to a vulnerable population” (Miller 2003,
253–254).
At first blush, this statement would seem to rule out the GH study because the placebo
arm of the study arguably involves nontherapeutic research that includes more than minimal risk
for the sake of possibly benefiting society and medicine. The problem here is twofold. First,
calculating risks and benefits before randomization leads to the conclusion that the study is
potentially beneficial and therapeutic, for all the children enrolled. If so, Miller’s comments here
cannot be interpreted as weighing against this study. Second, and more important, I am not sure
that Miller’s account helps us to see that the basic problem with the GH study is that it
presupposes that being short is a medical disorder. Commenting on the federal guidelines that
allow for a proportionate balance of risk and benefit in research that involves greater than
minimal risk, Miller writes: “. . . harm to individuals is justified in medical settings on the
condition that it is offset by the pursuit of patient benefit. I see no difficulty with this idea as it
applies to research with sick children” (Miller 2003, 251). I agree with this statement; I just do
not think the children in the GH study are “sick.” They are not hormone deficient, they do not
have Turner’s syndrome, and they are not suffering from chronic renal insufficiency. They are
simply short.⁷
As I indicated above, Miller does an admirable job showing that the concepts of
“minimal risk” and “minor increase over minimal risk” are “subject to widely different

interpretations by IRBs” and I endorse his call for a national commission that would, among
other things, seek to clarify these standards. But I wonder if the problem is not broader and
deeper than this. I wonder whether, in the absence of a comprehensive theory of the good, or at
least a thicker account of the good than Miller provides, we are able even to recognize how
bizarre it is to refer to being short as an “idiopathic” disorder. Whether or not Miller agrees with
me about the dangers of a thin theory of the good here, my hope is that this excellent volume will
lead to a sustained national conversation about pediatric ethics. As Miller skillfully demonstrates,
such a conversation is badly needed. Fortunately, with this volume we have a point of departure
(and an outline) for an extraordinarily fruitful conversation.
NOTES
1) I am indebted to Mark Sheldon at Northwestern University for bringing this issue to
my attention and for help in formulating the moral issues at stake here.
2) I wish I could report that Dr. Phil has moved away from this sort of voyeuristic
practice now that he has his own show, but a search of his web site suggests otherwise. A search
for the keyword “teen” returns 65 entries, including, among others, one for “Sex Talk: Shocking
Attitudes about Sex” and “Oral Sex from Teens Across America.”
3) One response that is open to Miller, of course, is to suggest that any practice that
exploits adolescent sexuality in this way will be ruled out by an overlapping consensus that
recognizes that fostering self-esteem in teenagers is necessary to healthy adult civic engagement
and thus is necessary for any society to flourish, no matter its conception of the comprehensive
good. The problem with this move is that our society seems not the least bit concerned about the
exploitation of adolescent sexuality in the way that this kind of response seems to require.
4) The discussion of the growth hormone study that follows was originally written in
collaboration with Martin Smith and is deeply indebted to his thoughtful analysis of this case.
5) Miller does an excellent job explaining how these standards appear to be but are not
clear.
6) One line of argument would be to suggest that subjects in the placebo arm stand to
benefit from a placebo effect and so, even apart from the kind of indirect benefits discussed by
the Review Committee, the placebo group can expect to receive direct benefit. The Review
Committee explicitly rejected this line of argument (National Institutes of Health 1992, 12).
7) I do not mean to dismiss the difficulties that result from being short, some of which
may involve considerable suffering. My point is that I do not think that shortness should be
defined as a “sickness.”
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